BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, Prada-Ramallal G. Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience. J Clin Med 2021;10:706. [PMID: 33670151 DOI: 10.3390/jcm10040706] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Cui X, Wang F, Liu C. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1062045] [Reference Citation Analysis]
2 Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, Mombaerts I, Salvi M, Stan MN. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J 2022;11:e220189. [PMID: 36479875 DOI: 10.1530/ETJ-22-0189] [Reference Citation Analysis]
3 Xu Q, Zhang X, Luo B, Li T, Yuan G, Shao S. Role of Peripheral Regulatory T Lymphocytes in Patients with Thyroid Associated Ophthalmopathy During Systemic Glucocorticoid Treatment: A Prospective Observational Study. CURR MED SCI 2022. [DOI: 10.1007/s11596-022-2671-8] [Reference Citation Analysis]
4 Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, Mombaerts I, Salvi M, Stan MN. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid 2022;32:1439-70. [PMID: 36480280 DOI: 10.1089/thy.2022.0251] [Reference Citation Analysis]
5 Pampín-Sánchez R, Martínez-Mugica-Barbosa C, Fonseca-Aizpuru EM, Barbazán-Vázquez FJ, Fernández-González B, Buznego-Súárez L. Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease. Med Clin (Barc) 2022:S0025-7753(22)00311-6. [PMID: 36088128 DOI: 10.1016/j.medcli.2022.05.007] [Reference Citation Analysis]
6 Wang X, Ye H, Yang S, Sha X, Wang X, Zhang T, Chen R, Xiao W, Yang H. Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves' Orbitopathy. Int J Mol Sci 2022;23:5261. [PMID: 35563653 DOI: 10.3390/ijms23095261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Atienza-mateo B, Prieto-peña D, Vicente-rabaneda EF, Blanco R, González-gay MA, Castañeda S. Utility of tocilizumab in autoimmune eye diseases. Expert Opinion on Biological Therapy. [DOI: 10.1080/14712598.2022.2066971] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ladsous M, Marks-delesalle C, Smirnov V, Guerreschi P. Orbitopathie basedowienne. Les Maladies de la Thyroïde 2022. [DOI: 10.1016/b978-2-294-77583-3.00014-9] [Reference Citation Analysis]
9 Mejía González MA, Carbone J. How suitable is intravenous tocilizumab for the treatment of Graves' ophthalmopathy? Expert Rev Clin Immunol 2021;17:1151-3. [PMID: 34704876 DOI: 10.1080/1744666X.2021.1997591] [Reference Citation Analysis]
10 Neag EJ, Smith TJ. 2021 update on thyroid-associated ophthalmopathy. J Endocrinol Invest 2021. [PMID: 34417736 DOI: 10.1007/s40618-021-01663-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
11 Tocilizumab. Reactions Weekly 2021;1851:343-343. [DOI: 10.1007/s40278-021-94433-2] [Reference Citation Analysis]